Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Profit After Tax: 2010-2025

Historic Profit After Tax for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$29.8 million.

  • Lineage Cell Therapeutics' Profit After Tax fell 881.58% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 235.95%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.39% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Profit After Tax of -$29.8 million as of Q3 2025, which was up 2.24% from -$30.5 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Profit After Tax registered a high of -$1.4 million during Q1 2021, and its lowest value of -$30.5 million during Q2 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Profit After Tax averaged around -$9.5 million, with its median value being -$5.2 million (2023).
  • Data for Lineage Cell Therapeutics' Profit After Tax shows a peak YoY increase of 83.14% (in 2021) and a maximum YoY decrease of 1,526.77% (in 2021) over the last 5 years.
  • Over the past 5 years, Lineage Cell Therapeutics' Profit After Tax (Quarterly) stood at -$29.0 million in 2021, then soared by 78.08% to -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 31.46% to -$3.3 million in 2024, then slumped by 881.58% to -$29.8 million in 2025.
  • Its last three reported values are -$29.8 million in Q3 2025, -$30.5 million for Q2 2025, and -$4.1 million during Q1 2025.